Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Doxycycline,Inapplicable
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg in the U.S.
Details : Oracea-Generic (doxycycline) is a tetracycline class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.
Product Name : Oracea-Generic
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 05, 2024
Lead Product(s) : Doxycycline,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxycycline,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PolyPid Completes Enrollment in Phase 3 SHIELD II Trial of D-PLEX100
Details : D-PLEX100, PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Product Name : D-Plex
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 11, 2025
Lead Product(s) : Doxycycline,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxycycline,Inapplicable
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endo Launches Doxycycline for Injection, USP
Details : Doxy 100-Generic (doxycycline) is a tetracycline class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : Doxycycline,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefixime,Azithromycin,Doxycycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Aurum Institute | Nyanza Reproductive Health Society | Partners for Health and Development in Africa | National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2024
Lead Product(s) : Cefixime,Azithromycin,Doxycycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Aurum Institute | Nyanza Reproductive Health Society | Partners for Health and Development in Africa | National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amivantamab,Lazertinib,Doxycycline,Minocycline Hydrochloride,Clindamycin Hydrochloride,Chlorhexidine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 07, 2023
Lead Product(s) : Amivantamab,Lazertinib,Doxycycline,Minocycline Hydrochloride,Clindamycin Hydrochloride,Chlorhexidine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxycycline,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 21, 2023
Lead Product(s) : Doxycycline,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxycycline,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Piramal Critical Care Announces the U.S. Launch of Doxycycline for Injection, USP
Details : Doxycycline for Injection, USP is a Protein 30S ribosomal subunit inhibitor, which is used for prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
Product Name : Doxycycline-Generic
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 16, 2023
Lead Product(s) : Doxycycline,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxycycline,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : NanoSHIFT
Deal Size : Inapplicable
Deal Type : Inapplicable
Investigation of Laser Assisted Drug Delivery of NanoDOX®
Details : Undisclosed
Product Name : NanoDOX
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 09, 2022
Lead Product(s) : Doxycycline,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : NanoSHIFT
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levofloxacin,Nitazoxanide,Doxycycline,Lansoprazole
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Future Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 11, 2022
Lead Product(s) : Levofloxacin,Nitazoxanide,Doxycycline,Lansoprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Future Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ivermectin,Doxycycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 28, 2021
Lead Product(s) : Ivermectin,Doxycycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable